Clinical Trial Update: Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 dose-de-escalation study of copanlisib combined with nivolumab and rituximab for relapsed/refractory indolent lymphoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Lymphoma

Drugs mentioned

• Copanlisib (copanlisib)
• Rituximab (rituximab)
• nivolumab (nivolumab)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Indolent Lymphoma | Phase 1 | Status: TERMINATED